The Massachusetts Health Policy Commission on released an analysis that found Question 1 would cost between $676 million and $949 million annually. Read the Patriot Ledger story.

At South Shore Medical Center, we know that trust and transparency are key to a strong relationship with your care provider. With that in mind, we wanted to acknowledge some of the challenges patients have experienced in recent months and discuss the steps we’re taking to address those challenges.

Two programs within the Grayken Center for Treatment at South Shore Health will transition to a new, spacious location at 797 Main Street, Weymouth. Learn more about the new location of the bridge program and perinatal behavioral health program.

Dr. Jason Tracy, Chief of Emergency Medicine at South Shore Hospital recently spoke with WCVB-TV about the opioid crisis in Massachusetts. Watch the video.

More than 390 business leaders and supporters of South Shore Health recently gathered at Pinehills Golf Club in Plymouth and Plymouth Country Club to help raise money for Behavioral Health and Substance Use Disorder (SUD) services on the South Shore. The South Shore Health annual Golf Classic, held...

South Shore Hospital, part of South Shore Health, has received an Innovator Award from the editors of Healthcare Innovation for its groundbreaking work in Clinical Pharmacy Practice by improving the medication reconciliation process.

Your Health, Our Passion, One Community. It’s our mission statement here at South Shore Health, and it has been our system’s guiding light as we’ve battled the COVID-19 pandemic. We are proud to serve residents of the South Shore because you are not only our patients, but our friends, our family...

Blue Cross Blue Shield of Massachusetts (Blue Cross) and South Shore Health System have launched a first-of-its-kind pilot program to improve patient care, slow the rise of health care costs, and change the way hospitals are paid.

The FDA has approved a new flu medication in the form of a single-dose pill. South Shore Hospital's Todd Ellerin, an infectious disease expert, spoke with ABC News and weighs-in on the new drug.